Intravitreal Aflibercept Injections In The Treatment Of Pattern Dystrophy

NAWithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 31, 2013

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions
Pattern Dystrophy of Macula
Interventions
DRUG

aflibercept

2.0 mg intravitreal aflibercept injection is formulated as a sterile liquid to a final concentration of 40 mg/mL aflibercept in 5% sucrose, 10 mM sodium phosphate pH 6.3, 0.03% polysorbate 20, and 40 mM NaClvs. placebo

Trial Locations (1)

10065

Ns/Lij Meeth, New York

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Northwell Health

OTHER

lead

Manhattan Eye, Ear & Throat Hospital

OTHER